grant | 2025 - 2029
A moonshot to accelerate bench to bedside rare diseases precision medicines
WA State Government
Grant no. 22666.
grant | 2025 - 2027
Bespoke antisense oligomer-mediated splice modulating therapies for recessive dystrophic epidermolysis bullosa patients
CureEB
Grant no. 22221.
grant | 2025 - 2027
Establishing a cell repository (biobank) for research purposes
Neuromuscular WA
Grant no. 22521.
grant | 2025 - 2025
Mini Brain Models of Childhood Neurological Disorders
Channel 7 Telethon Trust
Grant no. 22663.
grant | 2025 - 2029
Streamlining the development of antisense therapeutics for Western Australian children with rare genetic disorders
Stan Perron Foundation
Grant no. 22976.
grant | 2025 - 2028
Uncovering disease mechanisms and exploring therapies for muscular dystrophies
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 22917.
grant | 2025 - 2025
WA lightsheet microscopy facility for fast and gentle volumetric imaging
Australian Research Council (Australia, Canberra) - ARC
Grant no. 21676.
grant | 2024 - 2025
ASO-Mediated Therapeutic Intervention for Malan Syndrome (Year 2)
Malan Syndrome Foundation
Grant no. 21937.
grant | 2024 - 2025
CMMIT Capability Development Projects
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 22197.
grant | 2024 - 2025
Does Charge Matter - Investigating the Biodistribution of Morpholinos and Thio-Morpholinos
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 21949.
grant | 2024 - 2025
ORIGIO Mars IVF Safety Class 2 Workstation
Channel 7 Telethon Trust
Grant no. 21971.
grant | 2024 - 2024
Perron SPA Tooba Iqbal
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 22125.
grant | 2023 - 2027
An Innovative Approach to Modulate Alzheimers Disease Progression via Reduction of DYRK1A Activity Using Antisense Oligonucleotides.
Peacocke Foundation
Grant no. 22651.
grant | 2023 - 2026
Byron Kakulas Prestige Scholarships - Isabella Trew
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 21728.
grant | 2023 - 2024
NFIX upregulation validation in neuronally differentiated Malan patient-derived iPSC
RTW Charitable Foundation
Grant no. 21537.
grant | 2023 - 2023
Patient-derived Stem Cell Isolation: Establishment of Urine-Derived Cell Collection and Isolation
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 21491.
grant | 2023 - 2025
Sarepta 2023 - 2025
General
Grant no. 21339.
grant | 2022 - 2025
A new substrate reduction strategy to treat multiple childhood dementias: Glucosylceramide synthase-targeting antisense oligonucleotides
National Health and Medical Research Council (Australia, Canberra) - NHMRC
Grant no. 21230.
grant | 2022 - 2024
A targeted therapy for juvenile-onset Parkinsons disease patients arising from PARK2 mutations using splice-switching antisense oligonucleotides
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 21283.
grant | 2022 - 2023
DYRK1A Restoration for Childhood Intellectual Diseases: A Genetic Balancing Act
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 21290.
grant | 2022 - 2024
Humanised Mouse Model of Malan Syndrome
RTW Charitable Foundation
Grant no. 20818.
grant | 2022 - 2023
Live-cell imaging for childhood diseases
Channel 7 Telethon Trust
Grant no. 20948.
grant | 2022 - 2022
Modification of Midkine expression (Extension)
Lyramid Ltd
Grant no. 20895.
grant | 2022 - 2024
RAGE against Sepsis
Channel 7 Telethon Trust
Grant no. 21289.
grant | 2021 - 2022
Antisense Oligomer-Mediated Therapeutic Intervention for Malan Syndrome
Malan Syndrome Foundation
Grant no. 20124.
grant | 2021 - 2022
Lyramid: Modification of Midkine expression
Lyramid Ltd
Grant no. 20467.
grant | 2021 - 2022
Managing integrity alpha 4 mediated inflammation
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 20878.
grant | 2021 - 2022
The impact of chemical modifications of antisense oligomer on L1HS transposon element expression
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 20882.
grant | 2021 - 2022
Treatments for those who have none
Channel 7 Telethon Trust
Grant no. 20611.
grant | 2020 - 2021
AO drugs for diabetic complications
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 19815.
grant | 2020 - 2021
AO drugs in Parkinson's disease
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 19818.
grant | 2020 - 2021
AO drugs targeting transposable elements on ALS and other diseases
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 19814.
grant | 2020 - 2021
Converting astrocytes into dopaminergic neurons using splice-switching antisense oligomers: a potential treatment for Parkinsons disease
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 19864.
grant | 2019 - 2019
Exon skipping strategy as a treatment for recessive Ullrich Congenital Muscular Dystrophy
The Orphan Disease Center
Grant no. 18607.
grant | 2018 - 2019
Antisense mediated inhibition of PCSK9 activity: potential therapy for familial hypercholesterolemia
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 18588.
grant | 2016 - 2016
Antisense oligomer induced splice intervention targeting ITGA4 and LINGO1 as a combined treatment for multiple sclerosis.
Multiple Sclerosis Research Australia (Australia, North Sydney)
Grant no. 16641.
grant | 2015 - 2017
Scoping new exon skipping applications.
Sarepta Therapeutics (United States, Cambridge)
Grant no. 17048.